GSK Biologicals' influenza vaccine GSK2186877A — Competitive Intelligence Brief

GSK Biologicals' influenza vaccine GSK2186877A (GSK Biologicals' influenza vaccine GSK2186877A) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Influenza vaccine. Area: Immunology / Infectious Disease.

phase 3 Influenza vaccine Immunology / Infectious Disease Biologic

Target snapshot

GSK Biologicals' influenza vaccine GSK2186877A (GSK Biologicals' influenza vaccine GSK2186877A) — GlaxoSmithKline. GSK2186877A is an influenza vaccine that stimulates the immune system to produce antibodies and cellular immunity against influenza virus strains.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
GSK Biologicals' influenza vaccine GSK2186877A TARGET	GSK Biologicals' influenza vaccine GSK2186877A	GlaxoSmithKline	phase 3	Influenza vaccine
VaxigripTetra™ by Sanofi, Inc.	VaxigripTetra™ by Sanofi, Inc.	Centers for Disease Control and Prevention	marketed	Inactivated quadrivalent influenza vaccine
Hualan TIV	Hualan TIV	Sanofi	marketed	Inactivated influenza vaccine
Fluarix Tetra Vaccine	Fluarix Tetra Vaccine	GlaxoSmithKline	marketed	Inactivated influenza vaccine
Flublok™ Quadrivalent by Sanofi, Inc.	Flublok™ Quadrivalent by Sanofi, Inc.	Centers for Disease Control and Prevention	marketed	Recombinant inactivated influenza vaccine	Influenza hemagglutinin (HA) protein
Trivalent split Inf	Trivalent split Inf	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Inactivated influenza vaccine
Trivalent sub-unit influenza vaccine	Trivalent sub-unit influenza vaccine	University of Witwatersrand, South Africa	marketed	inactivated influenza vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Influenza vaccine class)

1. GlaxoSmithKline · 8 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
3. Seqirus · 2 drugs in this class
4. MedImmune LLC · 1 drug in this class
5. AstraZeneca · 1 drug in this class
6. Novartis · 1 drug in this class
7. Protein Sciences Corporation · 1 drug in this class
8. ModernaTX, Inc. · 1 drug in this class
9. Institute of Vaccines and Medical Biologicals, Vietnam · 1 drug in this class
10. Janssen Vaccines & Prevention B.V. · 1 drug in this class